Yeni tanı multipl myelomlu hastalarda otolog periferik hematopoetik kök hücre transplantasyonu: 32 hasta ile tek merkez deneyimi

Bu calişmada,yeni tanı 32 multipl myelom (MM) hastasında uygulanan otolog periferik hematopoetik kök hücre transplantasyonunun (OPKHT) yaşam süreleri üzerine etkisi araştırıldı. Tümör yükünü azaltmak için uygulanan VAD kemoterapisi sonrası 1 hasta dışında tüm hastalar siklofosfamid (2-4 g/m2)+büyüme faktörü ile mobilize edildi. Hazırlama rejimi olarak melfalan 200 mg/m2 (2 hastada 140mg /m2) kullanıldı. Transplantasyon ilişkili mortalite %9.3 (n=3) bulundu. Transplantasyon sonrası 13 hasta tam remisyonda (%40.6), 17 hasta kısmi yanıtta (%53.1) olarak değerlendirildi. Toplam yanıt oranı %93.4 bulundu. Medyan 27.6 aylık izlem süresinde, medyan total yaşam süresine henüz ulaşılmamış olup 5 yılda total sağkalım olasılığı %61; medyan "event-free survival" (EFS) 25 ay ve 4 yılda EFS olasılığı %36.1 saptandı. Bu sonuçlar, yeni tanı MM'lu hastalarda uygulanan OPKHT'nun yüksek oranda yanıt sağladığını ve yaşam süresini belirgin olarak uzattığını gösteren çalışmaların sonuçları ile uyumludur.

Autologous peripheral blood hematopoietic stem cell transplantation in newly diagnosed multiple myeloma patients: A single center experience with 32 patients

In this study, the effect of autologous peripheral blood hematopoietic stem cell transplantation (APBSCT) on the survival of 32 multiple myeloma (MM) patients. After VAD chemotherapy to reduce the tumor burden, all patients except one are mobilized by cyclophosphamide (2-4 g/m2)+ growth factor. Transplantation related mortality was 9.3% (n-3). Total response was 93.4% with 13 patients in complete remission (40.6%) and 17 patients in partial response (53.1%) after transplantation. In the follow-up period of median 27.6 months, it has not been reached to median overall survival, but overall surviral probability in 5 years is 61%,and median event-free survival (EFS)was 25 months.EFS in 4 years was found to be 36.1%.These results suggest that APBSCT in newly diagnosed MM patients,give a high response and are in correlation with the studies demonstrating that APBSCT lengthens the overall survival significantly.

___

  • 1. Boocadoro M, Pileri A. Diagnosis, prognosis, and standard treatment of multiple myeloma. Hematol Oncol Clin North Am 1997; 11: 111-131.
  • 2. Bataille R, Harousseau JL. Multiple myeloma. N Engl J Med 1997; 336: 1657-1664.
  • 3. Kovacsovics TJ, Delaly A. Intensive treatment strategies in multiple myeloma. Semin Hematol 1997; 34 (Suppl 1): 49-60.
  • 4. McElwain TJ, Powles RJ. High-dose intravenous melphalan for plasma-cell leukemia and myeloma. Lancet 1983; 2: 822-824.
  • 5. Jagannath S, Barlogie B. Autologous bone marrow transplantation for multiple myeloma. Hematol Oncol Clin North Am 1992; 6: 437-449.
  • 6. Gratwohl A, Baldomero H, Passweg J et al. For the Accredition Committe of the European Group for Blood and Marrow Transplantation. Hematopoietic stem celi transplantation for hematological malignancies in Europea. Leukemia 2003; 17: 941-959.
  • 7. Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomised trial of autologous bone marroW transplantation and chernotherapy in multiple myeloma. N Engl J Med 1996; 335: 91-97.
  • 8. Morgan GJ, Davies FE, Hawkins K et al. The MRC Myeloma VII Trial of standard versus intensive treatment in patients _____65 years of age with muitiple myeloma (abs). Blood 2002; 100: 178a.
  • 9. Urbano-lspizua A, Schmitz N, de Wİtte T et al. European Group for Blood and Marrow Transplantation. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe. Bone Marrow Transpiant 2002; 29: 639-646.
  • 10. Durie BGM, Salmon SE. Multiple myeloma, macroglobulinemia and monoclonal gammopathies. İn Hoffbrand AV, Brian MC, Hirsch J (eds): Recent Advances in Hematology, Churchill-Livingstone, Edinburgh, 1977; pp. 243-261.
  • 11. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma. Cancer 1975; 36: 842-854.
  • 12. Gregory WM, Richards MA, Malpas JS. Combination chenotherapy versus melphalan and prednisolone In the treatment of muitiple myeloma: an overvieWof published trials. J Clin Oncol 1992; 10: 334-342.
  • 13. Myeioma Triaiists' Collaborative Group. Combination chernotherapy versus melphalan plus prednisone as treatment fob multiple myeloma: an overvieW of 6633 patients from 27 randomised trials. J Clin Oncol 1998; 16: 3832-3842.
  • 14. Harousseau JL. Role of transplantation in myeloma. Hematology 2002, ASH Education Program Book 2002; 221-227.
  • 15. Fermand JP, Ravaud P, Katsahian S et al. High dose therapy and autologous blood stem celi transpiantation versus conventional treatment in multiple myeloma: results of a randomised trial in 190 patients 55 to 65 years of age (abs). Blood 1999; 94: 396a.
  • 16. Cunningham D, Paz-Ares L, Milan S et al. High-dose melphalan and autologous bone marroW transplantation as consolidation in previously untreated myeloma. J Clin Oncol 1994; 12 :759-763.
  • 17. Hajolino I, Vignetti M, Meloni G et al. Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Haematologica 1999; 84: 844-852.
  • 18. Rajkumar SV, Fonseca R, Lacy MQ 9t al. Beta2-microglobulin and bone marrow plasnıa celi involvernent predict complete responders among patients undergoing blood celi transplantation for myeloma. Bone Marrow Transplant 1999; 23: 1261-1266.
  • 19. Bensinger Wl, RoWley SD, Demirer T et al. High-dose therapy folloWed by autologous hematopoietic stem-cell infusion for patients With multiple myeloma. J Clin Oncol 1996; 14: 1484-1494.
  • 20. Siegel DS, Desikan KR, Hehta J et al. Age is not a prognostic variable With autotransplants fob multipie myeloma. Blood 1999; 3: 51-54.
  • 21. Badros A, Barlogie B, Siegel E et al. Autologous stem celi transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol 2001; 114: 600-607.
  • 22. Badros A, Barlogie B, Siegel E et al. Results of autologous stem cell transplant in multiple myeloma patients With renal failure. Br J Haematol 2001: 114: 822-829.
  • 23. Barlogie B, Jagannath S, Vesole DH et al. Superiority of tandem autologous transplantation over Standard therapy fob previousfy untreated multiple myeloma. Blood 1997; 89: 789-793.
  • 24. Barlogie B, Jagannath S, Desikan KR et al. Total therapy With tandem transplants fob newly diagnosed multipie myeloma. Blood 1999; 93: 55-65.
  • 25. Cavo M, Tosi P, Zamagni E et al. A multicentric randomized clinical trial comparing single vs double autologous peripheral blood stem celi (PBSC) transplantation (Tx) for patients With neWly diagnosed multiple myeloma:results of an inlerim analysis. Bone MarroW Transplant 2000; 25 (Suppl 1): S54.
  • 26. Attal M, Harousseau JL, Facon T et al. Double autologous transplantation improves survival of multiple myeloma patients: final analysis of a prospective randomized study of the "Intergroupe Francophone du Myeloma" (IFM 94). (abs) Biood 2002; 100:5a.
  • 27. Goldschmidt H, Bouko Y, Bourhis JH et al. CD34+ selected PBPCT in an increased infective risk Without prolongation of event free survival in neWly diagnosed myeloma: A randomised study from tha EBMT. (abs). Blood 2000; 96: 558a.
  • 28. SteWart AK, Vescio R, Schiller G et al. Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. J Clin Oncol 2001; 19: 3771-3779.
Ege Tıp Dergisi-Cover
  • ISSN: 1016-9113
  • Yayın Aralığı: Yılda 4 Sayı
  • Başlangıç: 1962
  • Yayıncı: Ersin HACIOĞLU
Sayıdaki Diğer Makaleler

Doppler bulguları eşliğinde normal ve hipertansif gebelerde plazma lipit profillerinin karşılaştırılması

Özgür ÖZTEKİN, Deniz CAN, Özer ÖZTEKİN, Zehra ADIBELLİ, Yusuf ABALI, Şivekar TINAR

Retroperitoneal sinovyal sarkom: Olgu sunumu

Seyran YİĞİT, Tuğba DOĞRULUK, Mine TUNAKAN, Umur YENSEL

Bir olgu nedeni ile kadın genital tüberkülozu. Olgu sunumu

Murat ULUKUŞ, Osman ZEKİOĞLU

Ultrastructural effects of nicotine administration on sympathetic nervous system of adrenal gland medula in fats: A qualitative study by electron microscopy

Hatice Kübra BAŞALOĞLU, HULKİ BAŞALOĞLU, MEHMET TURGUT, AYŞEGÜL UYSAL, Mine Ertem YURTSEVEN

Yeni tanı multipl myelomlu hastalarda otolog periferik hematopoetik kök hücre transplantasyonu: 32 hasta ile tek merkez deneyimi

Seçkin ÇAĞIRGAN, MUSTAFA PEHLİVAN, Ayhan DÖNMEZ

Tay-Sachs hastalığı; MR bulguları: Olgu sunumu

Serkan GÜR, BÜNYAMİN GÜNEY, Celal ÇINAR, Recep SAVAŞ

Meme kanserinde Kİ-67 ekspresyonu ve diğer prognostik faktörler ile ilişkisi

Veliddin Canfeza SEZGİN, Bülent KARABULUT, Ulus Ali ŞANLI, Rüçhan USLU, Erdem GÖKER, Selahattin SANAL, Necmettin ÖZDEMİR

Meme kanserinde C-ERBB-2 ekspresyonu ile diğer prognostik faktörler arasında ilişki var mı?

Bülent KARABULUT, Veliddin Canfeza SEZGİN, Ulus Ali ŞANLI, Rüçhan USLU, Erdem GÖKER, Necmettin ÖZDEMİR, Selahattin SANAL

Çocukta iskelet dışı mezenkimal kondrosarkom: Olgu sunumu

Zekeriya GÜMÜŞ, Neşe EKİNCİ, Seyran YİĞİT, Hasan KORKMAZ

İzmir Konak Doğumevi'ne istemli düşük için başvuran kadınların doğurganlık öyküleri ve aile planlaması davranışları

Nermin EROL, IŞIL ERGİN, Banu DÖNER, Durusoy Raika ONMUŞ, Nermin ŞAKRU, Üzeyir KIRCA